Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of DirectorsGlobeNewsWire • 06/12/23
Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing SiteGlobeNewsWire • 05/26/23
Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical TrialGlobeNewsWire • 05/21/23
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)GlobeNewsWire • 05/04/23
Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody TislelizumabGlobeNewsWire • 05/03/23
Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in ParisGlobeNewsWire • 04/26/23
Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual MeetingGlobeNewsWire • 04/04/23
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T CellsGlobeNewsWire • 03/31/23
Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment PoteGlobeNewsWire • 03/23/23
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate BankGlobeNewsWire • 03/11/23
ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14GlobeNewsWire • 03/06/23
Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA SubmissionGlobeNewsWire • 02/27/23
Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.GlobeNewsWire • 02/15/23
Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell MeetingGlobeNewsWire • 02/09/23
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced CancerGlobeNewsWire • 02/07/23
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialGlobeNewsWire • 01/13/23
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet ReachedGlobeNewsWire • 01/06/23
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell MeetingGlobeNewsWire • 12/28/22
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialGlobeNewsWire • 12/20/22
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid TumorsGlobeNewsWire • 12/19/22
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)GlobeNewsWire • 12/14/22
Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialGlobeNewsWire • 12/13/22
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient DosingGlobeNewsWire • 12/12/22
